Differential effects of Paclitaxel on dendritic cell function

BMC Immunology

Volumn 11, Issue , 2010, Pages

  John, Justin ^a   Ismail, Mohammed ^b   Riley, Catherine ^b   Askham, Jonathan ^c   Morgan, Richard ^b   Melcher, Alan ^c   Pandha, Hardev ^b  

^a Systems Biology Laboratory   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALLOANTIGEN; CELL SURFACE MARKER; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PACLITAXEL; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; INTERLEUKIN 12;

ARTICLE; CANCER RESISTANCE; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSKELETON; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; MELANOMA CELL; MICROARRAY ANALYSIS; MICROTUBULE; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

CANCER VACCINES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICROTUBULES; PACLITAXEL; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953701382     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-14     Document Type: Article

References (38)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-96. 10.1146/annurev.iy.09.040191.001415, 1910679.
2. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001, 106:271-4. 10.1016/S0092-8674(01)00448-2, 11509176.
3. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003, 30:23-9. 10.1016/S0093-7754(03)00229-X, 12881809.
4. Vermorken JB, Van Tendeloo VF. Dendritic cell therapy of cancer: can it fulfill its promise?. Expert Rev Anticancer Ther 2003, 3:1-3. 10.1586/14737140.3.1.1, 12597344.
5. Nestle J. The will to remember: the Lesbian Herstory Archives of New York. J Homosex 1998, 34:225-35. 10.1300/J082v34n03_12, 9505233.
6. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392:86-9. 10.1038/32183, 9510252.
7. Buttiglieri S, Galetto A, Forno S, De Andrea M, Matera L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer 2003, 106:516-20. 10.1002/ijc.11243, 12845646.
8. Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, Mellstedt H. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003, 17:894-9. 10.1038/sj.leu.2402913, 12750703.
9. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, Gabrilovich D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003, 9:285-94.
10. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 1995, 36:385-92. 10.1007/BF00686187, 7634380.
11. Ferrari S, Rovati B, Porta C, Alessandrino PE, Bertolini A, Collova E, Riccardi A, Danova M. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother 2003, 52:359-66.
12. Bhatti R, Ray P, Bell N. Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate. Urol Res 1991, 19:15-8. 10.1007/BF00294015, 2028560.
13. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000, 49:181-5. 10.1007/s002620000122, 10941900.
14. Gazit Z, Kedar E. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice. Cancer Immunol Immunother 1994, 38:243-52.
15. Nouza K, Sula K, Dvorak R, Svobodova M, Muller J, Sobotkova E. Preclinical screening and analysis of the immunotoxic and immunomodulatory activity using a multiple immunoassay (MIA) in mice. Int J Immunopharmacol 1990, 12:11-8. 10.1016/0192-0561(90)90063-S, 2105913.
16. Sardi A, Agnone C, Anderson G, Bolton JS, Sundgaard-Riise K, Nieroda C, Minton JP. Low-dose cyclophosphamide enhances helper-to-non-helper ratios. Cancer Detect Prev 1991, 15:217-24.
17. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87:21-7. 10.1038/sj.bjc.6600347, 2364288, 12085250.
18. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 2001, 61:7530-5.
19. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, Vogel SN. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol- inducible gene expression. J Immunol 2001, 166:574-81.
20. Wang J, Kobayashi M, Han M, Choi S, Takano M, Hashino S, Tanaka J, Kondoh T, Kawamura K, Hosokawa M. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br J Haematol 2002, 118:638-45. 10.1046/j.1365-2141.2002.03645.x, 12139759.
21. Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem 1996, 39:3889-96. 10.1021/jm9604080, 8831755.
22. Franchi L, Condo I, Tomassini B, Nicolo C, Testi R. A caspase like activity is triggered by LPS and is required for survival of human dendritic cells. Blood 2003, 102:2910-5. 10.1182/blood-2003-03-0967, 12829589.
23. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73. 10.1038/nri2216, 18097448.
24. Rubio MT, Ittelet D, Raymond E, Blay JY, Bernard J, Chouaib S. The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. Int J Oncol 2004, 25:407-12.
25. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987, 47:2486-93.
26. Joo HG. Altered maturation of dendritic cells by taxol, an anticancer drug. J Vet Sci 2003, 4:229-34.
27. Kim MH, Joo HG. The role of Bcl-xL and nuclear factor-kappaB in the effect of taxol on the viability of dendritic cells. J Vet Sci 2009, 10(2):99-103. 10.4142/jvs.2009.10.2.99, 2801113, 19461204.
28. Nakashima H, Tasaki A, Kubo M, Kuroki H, Matsumoto K, Tanaka M, Nakamura M, Morisaki T, Katano M. Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells. Cancer Chemother Pharmacol 2005, 55:479-87. 10.1007/s00280-004-0918-7, 15726369.
29. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004, 3:1301-10.
30. Leverkus M, McLellan AD, Heldmann M, Eggert AO, Brocker EB, Koch N, Kampgen E. MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways. Int Immunol 2003, 15:993-1006. 10.1093/intimm/dxg099, 12882837.
31. Bizario JC, Castro FA, Sousa JF, Fernandes RN, Damiao AD, Oliveira MK, Palma PV, Larson RE, Voltarelli JC, Espreafico EM. Myosin-V colocalizes with MHC class II in blood mononuclear cells and is up-regulated by T-lymphocyte activation. J Leukoc Biol 2002, 71:195-204.
32. Kuhn M. The microtubule depolymerizing drugs nocodazole and colchicine inhibit the uptake of Listeria monocytogenes by P388D1 macrophages. FEMS Microbiol Lett 1998, 160:87-90. 10.1111/j.1574-6968.1998.tb12895.x, 9495017.
33. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25:94-102. 10.1016/j.cyto.2003.10.004, 14698135.
34. Kim KD, Choe YK, Choe IS, Lim JS. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 2001, 69:426-34.
35. Uronen-Hansson H, Allen J, Osman M, Squires G, Klein N, Callard RE. Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and the Golgi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology 2004, 111:173-8. 10.1111/j.0019-2805.2003.01803.x, 1782406, 15027902.
36. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001, 31:2448-57. 10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N, 11500829.
37. Kawasaki K, Gomi K, Kawai Y, Shiozaki M, Nishijima M. Molecular basis for lipopolysaccharide mimetic action of Taxol and flavolipin. J Endotoxin Res 2003, 9:301-7.
38. Kovalcsik E, John J, Turner M, Birchall L, Sage D, Whittle R, Dalgleish A, Pandha H. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient. Melanoma Res 2004, 14:463-71. 10.1097/00008390-200412000-00005, 15577316.